Rite Aid vs Eli Lilly
Side-by-side comparison of AI visibility scores, market position, and capabilities
US pharmacy chain that emerged from Chapter 11 bankruptcy (filed October 2023) following $1.3B+ opioid settlements; competing with CVS and Walgreens with a restructured reduced store network.
About
Rite Aid is a US pharmacy retail chain — historically one of the three largest US drugstore networks alongside CVS and Walgreens — operating neighborhood pharmacies providing prescription medications, immunizations, health screenings, and personal care retail. Founded in 1962 in Scranton, Pennsylvania and headquartered in Camp Hill, Pennsylvania, Rite Aid filed for Chapter 11 bankruptcy protection in October 2023 under the combined pressure of opioid litigation settlements exceeding $1.3 billion, real estate liabilities from 2,200+ store leases, declining pharmacy reimbursement rates from PBMs, and debt from the 2007 acquisition of Eckerd pharmacies. Rite Aid emerged from bankruptcy in 2024 with a restructured balance sheet and reduced store network, closing hundreds of locations while maintaining operations in core markets.
Indianapolis global pharma (NYSE: LLY) at $45B 2024 revenue (+32%); first healthcare company to $1T market cap (Nov 2024) with Mounjaro/Zepbound tirzepatide (37% revenue) and oral GLP-1 orforglipron Phase 3 competing with Novo Nordisk.
About
Eli Lilly and Company is an Indianapolis, Indiana-based global pharmaceutical company — publicly traded on the New York Stock Exchange (NYSE: LLY) as an S&P 500 Dow Jones Industrial Average component — that in November 2024 became the world's most valuable pharmaceutical company with a historic $1 trillion market capitalization, the first healthcare company ever to reach this milestone. In fiscal year 2024, Lilly achieved approximately $45 billion in revenue, representing 32% growth from 2023, driven by blockbuster GLP-1 medications tirzepatide (Mounjaro for type 2 diabetes and Zepbound for obesity and obstructive sleep apnea), which together accounted for 37% of 2024 revenues. Other key products include Trulicity (dulaglutide, 12% of revenue), Humalog (insulin lispro, 5%), and Kisunla (donanemab), the first new Alzheimer's therapy approved for early symptomatic disease in 2024. An oral GLP-1 pill (orforglipron) is in Phase 3 clinical trials. CEO David Ricks has led the company since 2017. Founded in 1876 by Colonel Eli Lilly in Indianapolis, the company pioneered mass production of Jonas Salk's polio vaccine in 1955 and was among the first to produce human insulin using recombinant DNA technology.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.